Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Structure TherapeuticsGPCR +0.70%32 Cash Ratio is 25.59 as of Mar. 2026, which is 35% above its 10-year median of 18.89. GuruFocus rates GPCR with a GF Score™ of 32/100. Among 1,384 Biotechnology companies, Structure Therapeutics ranks better than 95.66% on this metric.
Structure Therapeutics has a Cash Ratio of 25.59. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Structure Therapeutics's Cash Ratio or its related term are showing as below:
GPCR'
s Cash Ratio Range Over the Past 10 Years
Min: 6.98 Med: 18.89 Max: 40.92
Current: 25.59
During the past 6 years, Structure Therapeutics's highest Cash Ratio was 40.92. The lowest was 6.98. And the median was 18.89.
GPCR's Cash Ratio is ranked better than 95.66% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs GPCR: 25.59
Structure Therapeutics (NAS:GPCR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Structure Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Structure Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Structure Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Structure Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Structure Therapeutics (GPCR) has a Cash Ratio of 25.59 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Structure Therapeutics and its competitors. This is 35% above median its historical median of 18.89. Over the past decade, Structure Therapeutics' Cash Ratio has ranged from 6.98 to 40.92. According to the industry distribution chart, Structure Therapeutics ranks #60 out of 1384 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Structure Therapeutics' Cash Ratio too high?
Structure Therapeutics' current Cash Ratio of 25.59 is 35% above median its 10-year median of 18.89. Over the past 10 years, this metric has ranged from a low of 6.98 to a high of 40.92. The Biotechnology industry median Cash Ratio is 2.94. Structure Therapeutics' value of 25.59 is 770.4% above this industry median. Based on the distribution chart, Structure Therapeutics ranks #60 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' Cash Ratio compare to PBLS and IDYA?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #60 out of 1384 companies for Cash Ratio. This places Structure Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Structure Therapeutics' value of 25.59 is 770.4% above this benchmark. Historically, Structure Therapeutics' own Cash Ratio has ranged from 6.98 to 40.92 over the past decade. While the company's 10-year median is 18.89 vs. the industry median of 2.94, Structure Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Structure Therapeutics's current Cash Ratio of 25.59 is 770.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Structure Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Structure Therapeutics's current Cash Ratio is 25.59, which is 35% above median its own 10-year median of 18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current Cash Ratio of 25.59. The current Cash Ratio is 25.59, which is 35% above median its 10-year median of 18.89 and 770.4% above the Biotechnology industry median of 2.94. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current Cash Ratio is 25.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score
Get the complete analysis for GPCR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GPCR has been successfully added to your 
